This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Analyst Blog: Archive
M&T Bank's Q3 Earnings on the Deck: Here's What You Should Know
by Zacks Equity Research
MTB is set to report Q3 results, with revenue and earnings expected to rise on stable lending and deposit trends.
STT MTB FHN
Levi Strauss' Q3 Earnings Beat Estimates, DTC Sales Up 11.3% Y/Y
by Zacks Equity Research
LEVI posts strong Q3 FY25 results with earnings and sales beats, powered by DTC and e-commerce strength.
URBN GCO LEVI BIRD
AppLovin Reinvents Itself: Betting Big on AI-Powered Advertising
by Zacks Equity Research
APP sheds its gaming past, betting its future on AI-driven ad tech with MAX and AXON at the core of its bold reinvention.
APP TTD MGNI
Duolingo: AI and Data Fueling Scalable Growth and a Lasting Edge
by Zacks Equity Research
DUOL's AI-powered content creation and data-driven personalization are fueling rapid expansion, stronger margins, and lasting competitive strength.
CHGG COUR DUOL
Victory Capital's September AUM Climbs 2.3% on Market Strength
by Zacks Equity Research
VCTR's AUM rose 2.3% in September to $310.6B, driven by market gains and strong growth in global equity and Solutions assets.
BEN IVZ VCTR
Landstar Continues to Grapple With Freight Market Weakness
by Zacks Equity Research
LSTR is hurt by reduced demand for freight services and increased truck capacity.
WAB GSL LSTR
J.B. Hunt Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
JBHT's third-quarter 2025 revenues are expected to decline year over year. Higher net interest expense might have hurt the bottom line.
UAL JBHT CHRW
BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow
by Zacks Equity Research
BDX teams with Opentrons to automate single-cell sequencing, advancing its multiomics and biosciences strategy.
BDX RMD MASI SOLV
Helen of Troy Q2 Earnings Beat Estimates, Sales Decline 9% Y/Y
by Zacks Equity Research
HELE's second-quarter earnings beat estimates despite a 9% y/y sales drop, with Olive & June helping offset weak Beauty & Wellness demand.
UNFI HELE VFF VITL
ExxonMobil's Financial Position: Here's What Investors Should Know
by Nilanjan Banerjee
XOM's robust balance sheet, low debt and strategic flexibility help it weather energy price swings and maintain shareholder rewards.
CVX XOM EOG
Enterprise Products Dips 2.1% in a Month: Bet on the Stock or Stay Away?
by Nilanjan Banerjee
Enterprise Products faces margin pressure from its Permian exposure and heavy debt load, raising questions about its investment appeal despite steady revenues.
EPD ENB KMI
Can Cybersecurity Innovations Help Backblaze Sustain Growth Ahead?
by Zacks Equity Research
BLZE's pivot to AI-driven cybersecurity tools positions it for strong enterprise growth and rising B2 demand.
DBX DDOG BLZE
Is Ouster Well-Poised to Capture the $19B Smart Infrastructure Market?
by Tanuka De
Ouster's software-driven LiDAR strategy and new global partnerships position it to seize the $19B smart infrastructure market opportunity.
LAZR OUST AEVA
Here's Why Investors Should Avoid Alaska Air Group Stock for Now
by Zacks Equity Research
ALK faces mounting cost pressures and weakening liquidity, eroding investor confidence and straining profitability.
ALK WAB GSL
How Crucial Are Managing Losses and LAE to Heritage's Profitability?
by Tanuka De
Heritage Insurance's sharper focus on managing losses, rate adequacy, and tech investments is driving stronger underwriting profitability.
HRTG KINS KNSL
Vistra Stock Outperforms Industry in a Year: How to Play?
by Jewel Saha
VST's 69% stock surge, rising earnings outlook and strong hedging strategy highlight its edge in the clean power transition.
NEE CEG VST
Baidu vs. Meta: Which AI Powerhouse is the Smarter Buy Right Now?
by Kashvi Chandgothia
BIDU leans into AI cloud and generative tools, as META delivers immediate returns with scaled AI across its platforms.
BIDU META
Can VZ Stock Profit From Starry's Expanded Fixed Wireless Access?
by Supriyo Bose
Verizon's planned Starry acquisition could double its fixed wireless base and expand broadband reach to 90M U.S. homes by 2028.
T VZ TMUS FYBR
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
by Zacks Equity Research
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
CDTX ALLO AKRO CMMB
Apogee Surpasses Earnings Estimates in Q2, Lowers FY26 Outlook
by Zacks Equity Research
APOG beats Q2 earnings and revenue estimates on UW Solutions gains but trims its FY26 outlook amid margin pressure.
OI APOG CR LIF
OXY to Sell OxyChem to Berkshire for $9.7B, Utilize Funds to Cut Debts
by Zacks Equity Research
Occidental to sell OxyChem to Berkshire for $9.7 billion, using proceeds to cut debt and strengthen its balance sheet.
COP OXY BRK.B NFG
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
by Kinjel Shah
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
JNJ AMGN TEVA KVUE
Microvast Skyrockets 119% YTD: Is It a Must-Have Stock Now?
by Arghyadeep Bose
MVST's sharp rally and bold battery breakthroughs are turning heads. Can the momentum last?
CMI OSK MVST
Accenture's GenAI Services: Will This Create Growth Wave?
by Arghyadeep Bose
ACN's Reinvention Services and expanding GenAI partnerships with Google and Microsoft are powering a surge in bookings and AI-driven growth.
ACN G LDOS
Will the Long-Range Model Y+ Help Tesla Catch Up in China?
by Rimmi Singhi
TSLA bets on the new long-range Model Y+ to revive its China sales as competition and price wars intensify.
TSLA NIO BYDDY XPEV